ATENT COOPERATION TR TY

	From the INTERNATIONAL BUREAU
PCT	To:
NOTIFICATION OF THE RECORDING OF A CHANGE (PCT Rule 92bis.1 and Administrative Instructions, Section 422) Date of mailing (day/month/year) 06 November 2001 (06.11.01)	BIRD GOEN & CO. Vilvoordsebaan 92 B-3020 Winksele BELGIQUE
Applicant's or agent's file reference D 1313 PCT	IMPORTANT NOTIFICATION
International application No. PCT/EP00/06345	International filing date (day/month/year) 05 July 2000 (05.07.00)
The following indications appeared on record concerning: The applicant the inventor	the agent the common representative
Name and Address ROCHE DIAGNOSTICS GMBH Sandhofer Strasse 116 D-68305 Mannheim Germany	State of Nationality State of Residence DE DE Telephone No.
	Facsimile No. Teleprinter No.
·	
2. The International Bureau hereby notifies the applicant that the X the person X the name X the add	(E)
Name and Address K.U. LEUVEN Groot Begijnhof 59 B-3000 Leuven	State of Nationality State of Residence BE BE Telephone No.
Belgium	Facsimile No.
	Teleprinter No.
3. Further observations, if necessary:	
4. A copy of this notification has been sent to: X the receiving Office the International Searching Authority X the International Preliminary Examining Authority	the designated Offices concerned X the elected Offices concerned other:
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740 14.35	Authorized officer Gabriele BAEHR Telephone No.: (41-22) 338.83.38

Form PCT/IB/306 (March 1994)

PATENT COOPERATION TF .TY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
FTATS LINIS DIAMERIQUE

Date of mailing (day/month/year) 01 March 2001 (01.03.01)	ETATS-UNIS D'AMERIQUE in its capacity as elected Office		
International application No. PCT/EP00/06345	Applicant's or agent's file reference D 1313 PCT		
International filing date (day/month/year) 05 July 2000 (05.07.00)	Priority date (day/month/year) 05 July 1999 (05.07.99)		
Applicant			
CAUWENBERGHS, Nancy et al			

1.	The designated Office is hereby notified of its election made:
	X in the demand filed with the International Preliminary Examining Authority on:
	05 January 2001 (05.01.01)
	in a notice effecting later election filed with the International Bureau on:
2.	The election X was
	was not
	made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

F. Baechler

Facsimile No.: (41-22) 740.14.35

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TH....ATY

	From the INTERNATIONAL BUREAU
PCT	То:
NOTIFICATION OF THE RECORDING OF A CHANGE (PCT Rule 92bis.1 and Administrative Instructions, Section 422) Date of mailing (day/month/year) 13 December 2001 (13.12.01)	BIRD GOEN & CO. Vilvoordsebaan 92 B-3020 Winksele BELGIQUE
Applicant's or agent's file reference D 1313 PCT	IMPORTANT NOTIFICATION
International application No. PCT/EP00/06345	International filing date (day/month/year) 05 July 2000 (05.07.00)
The following indications appeared on record concerning: X the applicant the inventor	the agent the common representative State of Nationality State of Residence
Name and Address K.U. LEUVEN	BE BE
Groot Begijnhof 59 B-3000 Leuven Belgium	Telephone No.
	Facsimile No.
•	Teleprinter No.
2. The International Bureau hereby notifies the applicant that the the person X the name the additional that the the person the additional that the person the person the additional that the person that the	
Name and Address	State of Nationality State of Residence BE BE
K.U. LEUVEN RESEARCH & DEVELOPMENT Groot Begijnhof 59 B-3000 Leuven Belgium	Telephone No.
Delgium	Facsimile No.
	Teleprinter No.
3. Further observations, if necessary:	
4. A copy of this notification has been sent to:	
X the receiving Office	the designated Offices concerned
the International Searching Authority	X the elected Offices concerned
the International Preliminary Examining Authority	other:
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Gabriele BAEHR Total base No. (41.20) 200.03.09



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 11 January 2001 (11.01.2001)

PCT

(10) International Publication Number WO 01/02853 A2

(51) International Patent Classification⁷:

- - -

B-9032 Gent (BE). VANHOORELBEKE, Karen [BE/BE]; Ommegangstraat 3, B-8550 Zwevegem (BE). DECKMYN, Hans [BE/BE]; Lemingstraat 1, B-3210

Linden (BE).

(21) International Application Number: PCT/EP00/06345

(74) Agent: VOSSIUS & PARTNER; Siebertstr. 4, D-81675 München (DE).

(81) Designated States (national): JP, US.

(22) International Filing Date:

5 July 2000 (05.07.2000)

(25) Filing Language:

English

G01N 33/48

(26) Publication Language:

English

(30) Priority Data:

99112967.7

5 July 1999 (05.07.1999) EF

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(71) Applicant (for all designated States except US): ROCHE DIAGNOSTICS GMBH [DE/DE]; Sandhofer Strasse 116, D-68305 Mannheim (DE).

Published:

 Without international search report and to be republished upon receipt of that report.

(72) Inventors; and
 (75) Inventors/Applicants (for US only): CAUWEN-BERGHS, Nancy [BE/BE]; Benningsbrugstraat 56A,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



ا م

(54) Title: DETECTION OF VON-WILLEBRAND FACTOR (vWF) ACTIVITY

(57) Abstract: The present invention relates to a method for detecting von-Willebrand factor (vWF) activity comprising assaying a sample in the presence of a soluble form or portion of glycoprotein $Ib(\alpha)$ (GPIb(α) and ristocetin, or a functionally equivalent substance. Additionally, the invention relates to the use of the aforementioned soluble form or portion of glycoprotein $Ib(\alpha)$, of ristocetin or a functional equivalent substance, of specifically reacting anti-GPIB(α) antibody(ies) and/or of specific binding partners, like specifically reacting anti-vWF antibody(ies) for carrying out the method of the invention. Furthermore, the present invention relates to kits for carrying out the method of the invention.

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 G01N33/86

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7-601N-C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

Further documents are listed in the continuation of box C.

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Ρ,Χ	VANHOORELBEKE KAREN ET AL: "A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor." THROMBOSIS AND HAEMOSTASIS, vol. 83, no. 1, January 2000 (2000-01), pages 107-113, XP000974940 ISSN: 0340-6245 the whole document	1-30
X	WO 92 16225 A (BRIGHAM & WOMENS HOSPITAL) 1 October 1992 (1992-10-01) page 38, paragraph 3 page 39, line 5,6 claim 17	1-30

Special categories of cited documents: A* document defining the general state of the art which is not considered to be of particular relevance.	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 E eartier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed 	 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
3 January 2001	25/01/2001
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Authorized officer Pellegrini, P

1

Patent family members are listed in annex.



inte onal Application No PCT/EP 00/06345

Category Citation of document, with indication, where appropriate, of the relevant passages X HOYLAERTS MARC F ET AL: "Promotion of binding of von Willebrand factor to	Relevant to claim No.
	1 22
platelet glycoprotein Ib by dimers of ristocetin." BIOCHEMICAL JOURNAL, vol. 306, no. 2, 1995, pages 453-463, XP000974675 ISSN: 0264-6021 cited in the application page 457, column 2, paragraph 3 -page 458, column 2, paragraph 1	1-30
US 5 231 033 A (FICKENSCHER KARL) 27 July 1993 (1993-07-27) the whole document	1-30

iformation on patent family members

Inte onal Application No PCT/EP 00/06345

Patent document cited in search repor	t	Publication date	ĺ	Patent family m mber(s)	Publication date
WO 9216225	Α	01-10-1992	US AU	5321127 A 1655092 A	14-06-1994 21-10-1992
US 5231033	Α	27-07-1993	DE AT	4016885 A 135109 T	28-11-1991 15-03-1996
		·	AU	655415 B	22-12-1994 28-11-1991
		· ·	AU CA	7621591 A 2043214 A	26-11-1991
			DE Ep	59107497 D 0458330 A	11-04-1996 27-11-1991
			ES JP	2085926 T 3018588 B	16-06-1996 13-03-2000
			JР	4231871 A	20-08-1992

PATENT COOPERATION TREATY

PCT

REC'D	17 OCT 2001
WIPO	PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant	's or ac	jent's file reference	T		O - North		
D 1313	_	•	FOR FURTHER A	CTION		ation of Transmittal of International Examination Report (Form PCT/IPEA/416))
Internatio	nal app	lication No.	International filing date (day/month	/year)	Priority date (day/month/year)	
PCT/EF	200/06	6345	05/07/2000			05/07/1999	
Internatio G01N3		ent Classification (IPC) or na	tional classification and IP	С			
Applicant			_				
ROCHE	DIA	GNOSTICS GMBH et a	1. K.U. LEUV	EN			
		ational preliminary exami smitted to the applicant a		prepared	by this Inte	rnational Preliminary Examining Autho	ority
2. This	REPO	ORT consists of a total of	6 sheets, including this	s cover sh	neet.		
	been a (see F	eport is also accompanied amended and are the bas dule 70.16 and Section 60 exes consist of a total of	is for this report and/or 7 of the Administrative	sheets co	ontaining red	a, claims and/or drawings which have ctifications made before this Authority e PCT).	
3. This	⊠	contains indications relat Basis of the report Priority					
IV		Non-establishment of op Lack of unity of invention		veity, inv	entive step a	ind industrial applicability	
v	⊠	•	der Article 35(2) with re		ovelty, inver	ntive step or industrial applicability;	
VI		Certain documents cited	•				
VII	\boxtimes	Certain defects in the.int	ternational application				
VIII	⊠	Certain observations on	the international applic	ation			
Date of sul	omissio	on of the demand		Date of c	ompletion of th	nis report	
05/01/20	01			12.10.20	01		
Name and preliminary	exami	address of the international ning authority: pean Patent Office		Authorize	d officer	September Mile	Niver Ele
	D-80	298 Munich		Weijlan	d, A		OFFW A
<u></u>		+49 89 2399 - 0 Tx: 523656 (+49 89 2399 - 4465	epmu a	Telenhon	e No. +49 89 2	2399 7490	**************************************

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/06345

 Basis of the repor 	l.	Bas	is o	f the	repor	t
--	----	-----	------	-------	-------	---

1.	the and	receiving Office in	nents of the international application (Replacement sheets which have been furnished to response to an invitation under Article 14 are referred to in this report as "originally filed" to this report since they do not contain amendments (Rules 70.16 and 70.17)):				
	1-2	8	as originally filed				
	Cla	ims, No.:					
	1-3	0	as originally filed				
	Dra	wings, sheets:					
	1/9	-9/9	as originally filed				
2.		•	uage, all the elements marked above were available or furnished to this Authority in the nternational application was filed, unless otherwise indicated under this item.				
	The	ese elements were a	evailable or furnished to this Authority in the following language: , which is:				
		the language of a t	ranslation furnished for the purposes of the international search (under Rule 23.1(b)).				
		the language of pu	blication of the international application (under Rule 48.3(b)).				
		the language of a t 55.2 and/or 55.3).	ranslation furnished for the purposes of international preliminary examination (under Rule				
3.			leotide and/or amino acid sequence disclosed in the international application, the y examination was carried out on the basis of the sequence listing:				
		contained in the int	ernational application in written form.				
		filed together with t	he international application in computer readable form.				
		furnished subseque	ently to this Authority in written form.				
		furnished subsequently to this Authority in computer readable form.					
			the subsequently furnished written sequence listing does not go beyond the disclosure in oplication as filed has been furnished.				
		The statement that listing has been fur	the information recorded in computer readable form is identical to the written sequence nished.				
4.	The	amendments have	resulted in the cancellation of:				
		the description,	pages:				
		the claims,	Nos.:				

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/06345

		the drawings,	sheets:
5.		•	established as if (some of) the amendments had not been made, since they have been yond the disclosure as filed (Rule 70.2(c)):
		(Any replacement sh report.)	neet containing such amendments must be referred to under item 1 and annexed to this
6	Δdd	litional observations i	f necessary:

- 6. Additional observations, if necessary
- V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- 1. Statement

Novelty (N) Yes: Cla

es: Claims 4,6,12,14,18,19,28,29

No: Claims 1-3,5,7-11,13,15-17,20-22,24-27,30

Inventive step (IS) Yes: Claims 23

No: Claims 1-22,24-30

Industrial applicability (IA) Yes: Claims 1-30

No: Claims

2. Citations and explanations see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted: see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made: see separate sheet

The following documents (D) are referred to in this report; the numbering will be adhered to the rest of the procedure:

- D1: VANHOORELBEKE KAREN ET AL: 'A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor.' THROMBOSIS AND HAEMOSTASIS, vol. 83, no. 1, January 2000 (2000-01), pages 107-113, XP000974940 ISSN: 0340-6245
- D2: WO 92 16225 A (BRIGHAM & WOMENS HOSPITAL) 1 October 1992 (1992-10-01)
- D3: HOYLAERTS MARC F ET AL: 'Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin.' BIOCHEMICAL JOURNAL, vol. 306, no. 2, 1995, pages 453-463, XP000974675 ISSN: 0264-6021 cited in the application

SECTION V

- 1. Novelty (Article 33(2) PCT)
- 1.1 The subject matter of claims 1-3,5,7-11,13,15-17, 20-22,24-27,30 is not novel.
 - Claims 1-3,5,7-11,13,15,16,20-22,24-27 are anticipated by D3. D3 (abstract; page 454, second and fourth paragraph) describes the interaction between purified vWF and GPIb ("method of detecting von-Willebrand factor activity" or "complex" according to present claims 1, 2,5). GP1b was purified from platelets after solubilization ("soluble" according to present claim 24) over an anti-GP1b antibody ("anti-GPIb) antibody" according to present claim 26) coated sepharose column. Purified GPIb ("glycoprotein $lb(\alpha)$ " according to present claim 1) was coated on wells of microtiter plates ("solid support", "plastic", "microtiter plate", "heterogeneous" according to present claims 3,10,11,13,15) and they were incubated with purified vWF from plasma ("blood sample", diluted" according to present claims 20 to 22) and ristocetin ("ristocetin" according to present claims 1 and 25). GPIb associated vWF was revealed by horse radish peroxidase conjugated anti-vWF monoclonal antibodies ("anti-vWT antibody" according to present claims 7, 8,9,27) in an ELISA assay ("ELISA" according to present claim 16).

Claims 1, 17 and 30 are anticipated by D2. D2 (abstract; page 42, second paragraph) describes recombinant Gplb(α) in an agglutination assay comprising a recombinant Gplb(α) polypeptide ("GP1b(α) is recombinantly produced" according to present claim 30) and vWF.

- 1.2 Claims 4,6,12,14,18,19,23, 28,29 are novel, since they are not disclosed in the prior art documents.
- 2. Inventive Step (Article 33(3) PCT).
- 2.1 Dependent claims 4, 6,12,14,18,19 do not contain any features which, in combination with the features of claim 1 to which they refer, meet the requirements of the PCT in respect of inventive step, since these features can be considered as mere alternatives for the skilled person in the art, without that they add to claim 1 any unexpected effect whatsoever.
- 2.2 Claims 28 and 29, relating to a kit or the use thereof comprising the components (a) to (d), do not involve an inventive step, since it would be obvious for the skilled person to bring together in the form of a kit, the components needed to carry out a non-inventive method. A kit for a non-inventive method itself is thus not inventive.
- 2.3 Claim 23 would appear to involve an inventive step.

D3 (see section 1.1 above) is considered to be the closest prior art. Claim 23 differs from D3 in that it relates to a method for discrimination between von Willebrand disease typ I and II in that it determines the total amount of vWF antigen and the vWF activity in a test sample.

The technical problem to be solved would reside in further applications of the vWF activity assay to overcome problems known in the prior art accompanied with these assays (see pages 2 to 4 of the description).

The skilled person, equipped with the knowledge of D3, would not be motivated to arrive at the subject matter of claim 23, since it has not been suggested in D3 alone or in combination with any other prior art document, that discrimination

EXAMINATION REPORT - SEPARATE SHEET

between vWF type I and vWF type II can be accomplished by steps (a) to (d) and moreover that means are thus provided for a more reproducible and more precise test with low inter and intra-assay variability (see page 5, second paragraph of the description).

3. The priority date of the present application, i.e. 05.07.1999, is validly claimed and therefore D1 does not form part of the state of the art.

SECTION VII

4. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in D2 is not mentioned in the description, nor are these documents identified therein.

SECTION VIII

- 5. The passage "or a functional equivalent substance" renders the subject matter of claim 1 for which protection is sought unclear and contravenes Article 6 PCT.
- 6. The use of optionally features in the passage "optionally further comprising...." renders the subject matter that follows this passage non limiting for the scope of claim 29 and introduces ambiguity in said scope and so contravenes Article 6 PCT.

PATENT COOPERATION TREA

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference		of Transmittal of International Search Report 20) as well as, where applicable, item 5 below.				
D 1313 PCT International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)				
PCT/EP 00/06345	05/07/2000	05/07/1999				
Applicant						
ROCHE DIAGNOSTICS GMBH et	al.					
This International Search Report has been according to Article 18. A copy is being tra	n prepared by this International Searching Aut ansmitted to the International Bureau.	nority and is transmitted to the applicant				
This International Search Report consists X It is also accompanied by	of a total of3 sheets. a copy of each prior art document cited in this	report.				
Basis of the report						
	international search was carried out on the bar ess otherwise indicated under this item.	sis of the international application in the				
the international search w Authority (Rule 23.1(b)).	as carried out on the basis of a translation of t	he international application furnished to this				
was carried out on the basis of the	e sequence listing :	nternational application, the international search				
	onal application in written form.	_				
	rnational application in computer readable form	n.				
furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readble form.						
the statement that the sub	the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.					
``		s identical to the written sequence listing has been				
2. Certain claims were fou	nd unsearchable (See Box I).					
3. Unity of invention is lack	king (see Box II).					
4. With regard to the title,						
the text is approved as su	bmitted by the applicant.					
X the text has been establis	hed by this Authority to read as follows:					
DETECTION OF VON-WILLE	BRANDFACTOR (VWF) ACTIVITY					
5. With regard to the abstract,						
	bmitted by the applicant. hed, according to Rule 38.2(b), by this Authori date of mailing of this international search rep					
6. The figure of the drawings to be publi		1				
as suggested by the appli		None of the figures.				
X because the applicant faile						
because this figure better	characterizes the invention.					

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 G01N33/86

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{array}{ccc} \text{Minimum documentation searched (classification system followed by classification symbols)} \\ IPC & 7 & G01N & C07K \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	VANHOORELBEKE KAREN ET AL: "A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor." THROMBOSIS AND HAEMOSTASIS, vol. 83, no. 1, January 2000 (2000-01), pages 107-113, XP000974940 ISSN: 0340-6245 the whole document	1-30
X	WO 92 16225 A (BRIGHAM & WOMENS HOSPITAL) 1 October 1992 (1992-10-01) page 38, paragraph 3 page 39, line 5,6 claim 17	1-30

Further documents are listed in the continuation of box C.	χ Patent family members are listed in annex.
Special categories of cited documents: A* document defining the general state of the art which is not considered to be of particular relevance E* earlier document but published on or after the international filling date L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) O* document referring to an oral disclosure, use, exhibition or other means P* document published prior to the international filling date but later than the priority date claimed	 *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
3 January 2001	25/01/2001
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Pellegrini, P



ernational Application No
PCT/EP 00/06345

ategory °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HOYLAERTS MARC F ET AL: "Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin." BIOCHEMICAL JOURNAL, vol. 306, no. 2, 1995, pages 453-463, XP000974675 ISSN: 0264-6021 cited in the application page 457, column 2, paragraph 3 -page 458, column 2, paragraph 1	1-30
A	US 5 231 033 A (FICKENSCHER KARL) 27 July 1993 (1993-07-27) the whole document	1-30
	· .	·

NT NATIONAL SEARCH REPORT

mormation on patent family members

ernational Application No
PCT/EP 00/06345

Patent document cited in search report	t	Publication date	1	Patent family member(s)	Ì	Publication date
WO 9216225	Α	01-10-1992	US AU	5321127 A 1655092 A	·	14-06-1994 21-10-1992
US 5231033	A	27-07-1993	DE AT AU CA DE EP ES JP JP	4016885 A 135109 T 655415 B 7621591 A 2043214 A 59107497 D 0458330 A 2085926 T 3018588 B 4231871 A	•	28-11-1991 15-03-1996 22-12-1994 28-11-1991 26-11-1991 11-04-1996 27-11-1991 16-06-1996 13-03-2000 20-08-1992